Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Halia TherapeuticsHalia Therapeuticsto Participate in the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 ForumHalia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to participate in the 6th Annual Needham Private Biotech...
- MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerEnrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
- SoliusSolius Labs Named to Fast Company's 2026 Next Big Things in Tech ListRecognition highlights the first FDA-cleared, over-the-counter personalized UVB light therapy device — Solius Labs, the world's only Personalized Sunlight company, today announced that Solius Pro, the only FDA-cleared personalized UVB...
- Hagens Berman Sobol Shapiro LLPHims & Hers Health (HIMS) Alert: Securities Fraud Class Action Filed, Investors Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff DeadlineHims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business...
- Hagens Berman Sobol Shapiro LLPBeta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA ComplianceBeta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit follows a...
- VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsAs the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
- Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS
- AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced an oral presentation at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. The presentation will feature new data from AltruBio’s Phase 2a ASCEND UC2a trial (NCT06109441) evaluating its lead asset, ALTB-268, in patients with moderately to severely active ulcerative colitis with an inadequate response to prior advanced therapy.
- Akebia Therapeutics, Inc.Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumCompanies: U.S. BancorpAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
- Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsJasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled.
- CTF Life Establishes Strategic Partnership with HKMC Annuity to Expand Retirement Planning Options and Empower More Fulfilling RetirementsHONG KONG, Oct 7, 2026 - CTF Life today announced a strategic partnership with HKMC Annuity Limited ("HKMCA"). By combining their respective expertise in retirement planning and life insurance, the partnership will further broaden retirement planning options for customers, empowering them to better prepare for the future and enjoy a more fulfilling retirement. CTF Life and HKMCA will also collaborate on thematic seminars, customer engagement events and financial education programmes to enhance public awareness of longevity risk, retirement income planning and asset allocation. Hong Kong's population continues to age. According to the 2026 Policy Address, the number of people aged 65 and above is projected to reach 2.74 million by 2046, accounting for more than one-third of the city's population1. As demand for stable retirement income and long-term financial protection continues to grow, the importance of early and holistic retirement planning is becoming increasingly evident. Through this partnership, CTF Life and HKMCA will combine their expertise in retirement planning, life protection and retirement income management to help the public build more resilient and well-rounded retirement plans. Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said: "At CTF Life, customers are at the heart of everything we do. We are committed to supporting customers and their loved ones throughout the life journey of 'Wellbeing, Growth, Health and Wealth' with personalised planning solutions, lifelong protection and diverse lifestyle experiences. Building on our existing protection and wealth management solutions, this collaboration provides eligible customers with an additional avenue to learn more about the HKMC Annuity Plan2, further broadening their retirement planning options. By combining our strengths with HKMCA, we hope to raise public awareness of the importance of early retirement planning and help more people build greater financial confidence for retirement and enjoy a more fulfilling retirement life." Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (left), and Daniel Leong, Executive Director and Chief Executive Officer of HKMCA (right), announced a strategic partnership to expand customers’ retirement planning options and help them enjoy a more fulfilling retirement. (From left to right) Eleonore Chow, Chief Executive, Agency of CTF Life; Ellick Tsui, JP, Executive Director and Deputy Chief Executive Officer and Chief Financial Officer of CTF Life; Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life; Daniel Leong, Executive Director and Chief Executive Officer of HKMCA; Kelvin Lee, Chief Operating Officer of HKMCA; and Melinda Chan, Head of Business and Channel Development of HKMCA. Daniel Leong, Executive Director and Chief Executive Officer of HKMCA, said: "HKMCA has always been committed to helping the public manage longevity risk and providing retirees with a stable, lifelong source of income. Through our partnership with CTF Life, we hope to further expand the reach of retirement planning education, enabling more people to understand the importance of managing retirement income and the role that annuity products can play in retirement planning." As a member of Chow Tai Fook Enterprises Limited, CTF Life leverages the Group's ecosystem to provide customers and their loved ones with comprehensive protection and financial planning solutions. Its insurance solutions and value-added services span wellbeing, growth, health and wealth, helping customers achieve their aspirations at every stage of life, empowering them to plan confidently for the future and live fulfilling, enriched lives. Notes: 1. Source: The 2026 Policy Address 2. The HKMC Annuity Plan is operated by HKMC Annuity Limited, a wholly-owned subsidiary of The Hong Kong Mortgage Corporation Limited. For further information, please refer to the HKMC Annuity Limited website: www.hkmca.hk. Important Notice: - For further details, please contact CTF Life’s Customer Service Hotline on +852 2866 8898. - This press release is intended to be distributed in Hong Kong only and shall not be construed as an offer to sell or a solicitation to buy or provision of any of our products outside Hong Kong. Chow Tai Fook Life Insurance Company Limited hereby declares that it has no intention to offer to sell, to solicit to buy or to provide any of its products in any jurisdiction other than Hong Kong in which such offer to sell or solicitation to buy or provision of any product of Chow Tai Fook Life Insurance Company Limited is illegal under the laws of that jurisdiction.
- VSIVSI® Expands Surgical Capabilities to Meet Growing Patient Demand, Welcomes Spine Surgeon Dr. Alexander Upfill-BrownHSS-trained orthopedic spine surgeon adds surgical capacity and minimally invasive expertise as more patients seek care at the Reston spine center. — VSI Spine Solutions (formerly Virginia Spine Institute) announced that orthopedic spine surgeon...